Investment
Features
FeesSafety
Academy
More
Pluang+

Compare VanEck Gold Miners ETF (GDX) vs Moderna, Inc. (MRNA) Price & Performance

VanEck Gold Miners ETFTrade
Moderna, Inc.Trade

Price performance (Past 24H)

Key statistics

VanEck Gold Miners ETF vs Moderna, Inc. — how do they compare? VanEck Gold Miners ETF trades at $90.95, while Moderna, Inc. trades at $63.88 (market cap $24.18B). The key difference: Moderna, Inc. is trading nearer its 52-week high, VanEck Gold Miners ETF nearer its low. Which is the better fit depends on your goals.

GDXMRNA
52-Week High
$115.84$81.80
52-Week Low
$56.60$22.36
Market Cap
$24.18B
Sector
Health
Enterprise Value
$20.33B

Aura AI Summary

Signals from Pluang's Aura AI — not financial advice

VanEck Gold Miners ETF

GDX, the VanEck Gold Miners ETF, trades at $91.15, up 0.73% today, with a bullish technical signal from moving averages but overbought RSI readings. Recent news highlights institutional repositioning and strong gold price momentum driving miner performance. The ETF provides diversified exposure to gold mining equities amid a seven-week gold rally near $4,300 per ounce.

Outlook is positive given gold's strength, but risks include volatility from Fed policy shifts and miner underperformance versus bullion. Analyst sentiment is mixed, with some advocating for value while others caution on stretched valuations. Upside depends on sustained gold prices and mining operational efficiency.

Moderna, Inc.

Moderna (MRNA) trades at $63.57, up 6.29% on the day, reflecting positive momentum following FDA approval of its mRNA flu vaccine, mFLUSIVA, for adults 50 and older. The stock exhibits a bullish technical outlook with moving averages supporting upward movement, though RSI levels suggest potential overbought conditions. Fundamentally, revenue has declined from pandemic peaks, with 2025 revenue at $1.92B and a net loss of -$2.82B, yet the company has beaten EPS estimates in recent quarters. Cash flow trends show improvement, with net cash flow turning positive in 2025 at $668M.

The outlook for MRNA hinges on pipeline execution beyond COVID-19, with recent vaccine approvals providing growth catalysts. Investment opportunities include diversification into flu, Ebola, and oncology therapies, but risks persist from high cash burn, competitive pressures, and reliance on successful clinical trials. Analyst sentiment is mixed with a consensus price target of $54.33, below the current price, indicating caution despite some bullish developments.

Returns comparison

Trailing returns across standard periods

Top news

Latest headlines on both assets

About VanEck Gold Miners ETF

The fund normally invests at least 80% of its total assets in common stocks and depositary receipts of companies involved in the gold mining industry. The index is a modified market-capitalization weighted index primarily comprised of publicly traded companies involved in the mining for gold and silver. The fund is non-diversified.

Read more on GDX

About Moderna, Inc.

Moderna, Inc. operates as a clinical stage biotechnology company. The Company focuses on the discovery and development of messenger RNA (mRNA) therapeutics and vaccines. Moderna develops mRNA medicines for infectious, immuno-oncology, and cardiovascular diseases.

Read more on MRNA